Translating the promise of 5HT 4 receptor agonists for the treatment of depression

32Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

Animal experimental studies suggest that 5-HT4 receptor activation holds promise as a novel target for the treatment of depression and cognitive impairment. 5-HT4 receptors are post-synaptic receptors that are located in striatal and limbic areas known to be involved in cognition and mood. Consistent with this, 5-HT4 receptor agonists produce rapid antidepressant effects in a number of animal models of depression, and pro-cognitive effects in tasks of learning and memory. These effects are accompanied by molecular changes, such as the increased expression of neuroplasticity-related proteins that are typical of clinically useful antidepressant drugs. Intriguingly, these antidepressant-like effects have a fast onset of their action, raising the possibility that 5-HT4 receptor agonists may be a particularly useful augmentation strategy in the early stages of SSRI treatment. Until recently, the translation of these effects to humans has been challenging. Here, we review the evidence from animal studies that the 5-HT4 receptor is a promising target for the treatment of depression and cognitive disorders, and outline a potential pathway for the efficient and cost-effective translation of these effects into humans and, ultimately, to the clinic.

Cite

CITATION STYLE

APA

Murphy, S. E., De Cates, A. N., Gillespie, A. L., Godlewska, B. R., Scaife, J. C., Wright, L. C., … Harmer, C. J. (2021, May 1). Translating the promise of 5HT 4 receptor agonists for the treatment of depression. Psychological Medicine. Cambridge University Press. https://doi.org/10.1017/S0033291720000604

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free